25-hydroxyprotopanaxadiol has been researched along with Cirrhosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, X; Li, X; Liu, LP; Piao, HR; Xing, DL; Zhang, QG; Zhao, YQ; Zhou, S | 1 |
1 other study(ies) available for 25-hydroxyprotopanaxadiol and Cirrhosis
| Article | Year |
|---|---|
The novel ginsenoside AD2 prevents angiotensin II-induced connexin 40 and connexin 43 dysregulation by activating AMP kinase signaling in perfused beating rat atria.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Connexin 43; Connexins; Down-Regulation; Fibrosis; Gap Junction alpha-5 Protein; Gap Junctions; Ginsenosides; NF-kappa B; Rats; Rats, Sprague-Dawley; Signal Transduction; Transcription Factor AP-1; Transforming Growth Factor beta1; Up-Regulation | 2021 |